Highbridge Capital Management’s Coherus Oncology CHRS Stock Holding History

Highbridge Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-375,000	Closed	-$4.14M	–	970
2018 Q1	$4.14M	Buy	+375,000	New	+$4.1M	0.07%	321
2017 Q4	–	Sell	-33,906	Closed	-$453K	–	1671
2017 Q3	$453K	Sell	33,906 -9,950	-23%	-$132K	0.01%	982
2017 Q2	$630K	Buy	43,856 +27,377	+166%	+$527K	0.01%	688
2017 Q1	$349K	Buy	+16,479	New	+$405K	0.01%	1074
2016 Q2	–	Sell	-12,064	Closed	-$256K	–	1434
2016 Q1	$256K	Buy	+12,064	New	+$198K	﹤0.01%	1242

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's CHRS Position: Q2 2018 in Review

Highbridge Capital Management sold out of Coherus Oncology (CHRS) in Q2 2018, closing a stake of 375,000 shares — an estimated $4.14M sold.

Highbridge Capital Management first reported a position in CHRS in Q1 2016 and held it in 5 quarters. The position peaked at $4.14M in Q1 2018. 115 funds tracked by Wall St. Rank hold CHRS as of Q2 2018.

Highbridge Capital Management reported no remaining Coherus Oncology position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 375,000 Coherus Oncology shares in Q2 2018, an estimated $4.14M.
Highbridge Capital Management first reported a position in Coherus Oncology in Q1 2016 and held it in 5 quarters.
Highbridge Capital Management's Coherus Oncology position peaked at $4.14M in Q1 2018.
115 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.